hydroxyproline has been researched along with Menopause in 118 studies
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A longitudinal study was performed to document the effect of surgical menopause and postmenopausal etidronate disodium therapy on several nonhistomorphometric indices of bone turnover." | 9.06 | Effect of etidronate disodium on bone turnover following surgical menopause. ( Bevan, J; Fogelman, I; Hart, DM; Leggate, I; Scott, E; Smith, ML, 1989) |
| " To explore a possible relationship between parathormone action on bone and estrogens we studied the activity of the bone isoenzyme of serum alkaline phosphatase and the urinary excretion of hydroxyproline in 16 premenopausal and 24 postmenopausal women with primary hyperparathyroidism with hyperparathyroid osteodystrophy." | 7.67 | The activity of the bone isoenzyme of serum alkaline phosphatase and urinary hydroxyproline excretion in premenopausal and postmenopausal women with primary hyperparathyroidism. ( Broulik, PD; Pacovský, V; Stĕpán, J, 1984) |
| "The effects of norethindrone (5 mg daily) on biochemical variables and forearm mineral density were assessed in 20 postmenopausal women with mild primary hyperparathyroidism." | 7.67 | Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density. ( Horowitz, M; Morris, H; Need, AG; Nordin, BE; Philcox, J; Wishart, J, 1987) |
| "Treatment with ethinyl estradiol or norethindrone reduces the bone-turnover rate and plasma calcium levels in normal postmenopausal women, without affecting the secretion of calcium-regulating hormones." | 5.27 | Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. ( Peacock, M; Selby, PL, 1986) |
| "A longitudinal study was performed to document the effect of surgical menopause and postmenopausal etidronate disodium therapy on several nonhistomorphometric indices of bone turnover." | 5.06 | Effect of etidronate disodium on bone turnover following surgical menopause. ( Bevan, J; Fogelman, I; Hart, DM; Leggate, I; Scott, E; Smith, ML, 1989) |
| "The effects on calcium metabolism and forearm bone mineral density of sequential transdermal estradiol (ESTRADERM TTS-50), 50 micrograms/day and medroxyprogesterone (10 mg/day for 12 days) was studied in a randomised controlled trial in 34 healthy females 2-4 years after the menopause." | 5.06 | Transdermal estradiol in the treatment of postmenopausal bone loss. ( Adami, S; Bertoldo, F; Lo Cascio, V; Maresca, V; Residori, M; Rossini, M; Suppi, R, 1989) |
| "We studied the relation between common inexpensive markers of bone turnover (serum alkaline phosphatase (ALP), osteocalcin (OC), urinary hydroxyproline (OHPr), and calcium (Ca)), BMD, age, and menopause in a combined cross-sectional and longitudinal design comprising 429 pre- and postmenopausal randomly selected women aged 21-79 years (mean 50 years)." | 3.73 | Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study. ( Larsson, L; Löfman, O; Magnusson, P; Toss, G, 2005) |
| " Measurements were made of serum electrolytes, PTH and biochemical indices of bone turnover: serum osteocalcin and alkaline phosphatase and fasting urinary hydroxyproline and calcium." | 3.68 | Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement. ( Akerström, G; Joborn, C; Larsson, K; Lindh, E; Ljunghall, S; Naessén, T; Rastad, J; Wide, L, 1991) |
| " To explore a possible relationship between parathormone action on bone and estrogens we studied the activity of the bone isoenzyme of serum alkaline phosphatase and the urinary excretion of hydroxyproline in 16 premenopausal and 24 postmenopausal women with primary hyperparathyroidism with hyperparathyroid osteodystrophy." | 3.67 | The activity of the bone isoenzyme of serum alkaline phosphatase and urinary hydroxyproline excretion in premenopausal and postmenopausal women with primary hyperparathyroidism. ( Broulik, PD; Pacovský, V; Stĕpán, J, 1984) |
| "The effects of norethindrone (5 mg daily) on biochemical variables and forearm mineral density were assessed in 20 postmenopausal women with mild primary hyperparathyroidism." | 3.67 | Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density. ( Horowitz, M; Morris, H; Need, AG; Nordin, BE; Philcox, J; Wishart, J, 1987) |
| "Fasting plasma and urinary calcium and urinary hydroxyproline are known to rise at the menopause, reflecting increased bone resorption." | 3.66 | The effect of oestradiol valerate and cyclic oestradiol valerate/DL-norgestrel on calcium metabolism. ( Crilly, RG; Marshall, DH; Nordin, BE, 1978) |
| "Triiodothyronine (T3) was administered to the two groups as 20 micrograms doses three times daily for 7 days." | 2.68 | Skeletal responsiveness to thyroid hormone is not altered at menopause. ( Charles, P; Eriksen, EF; Langdahl, BL; Loft, AG; Mosekilde, L; Møller, N; Weeke, J, 1996) |
| "Women with increased bone resorption induced by bilateral oophorectomy 1-5 years previously (of a total of 48 women in the study, 20 were controls, and 28 were the treatment group) were studied during a 3 year follow-up." | 2.66 | Prospective trial of ossein-hydroxyapatite compound in surgically induced postmenopausal women. ( Pacovský, V; Pospíchal, J; Presl, J; Stĕpán, JJ, 1989) |
| " It is likely that a higher dosage would be more effective, but would cause the potential endometrial effects." | 2.65 | Bone loss during oestriol therapy in postmenopausal women. ( Clark, AC; Garwood, J; Hart, DM; Kraszewski, A; Lindsay, R; Maclean, A, 1979) |
| "Assessment of bone resorption can be achieved with measurement of urinary hydroxyproline, urinary excretion of the pyridinium crosslinks (Pyr and D-Pyr), and by measurement of plasma TRAP activity." | 2.38 | What do we know about biochemical bone markers? ( Delmas, PD, 1991) |
| "The menopause is associated with a rise in obligatory urinary calcium loss resulting from an increase in the filtered load of calcium which may be due to the complexed fraction." | 2.37 | Calcium and osteoporosis. ( Horowitz, H; Morris, HA; Need, AG; Nordin, BE; Polley, KJ, 1988) |
| "m." | 1.31 | Effects of dose and timing of calcium supplementation on bone resorption in early menopausal women. ( Horowitz, M; Morris, HA; Need, AG; Nordin, BE; Scopacasa, F; Wishart, JM, 2002) |
| "There was a transient further rise in bone resorption for the 10 years following menopause." | 1.29 | The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90. ( Criddle, A; Devine, A; Dick, I; Garcia-Webb, P; Gutteridge, DH; Kerr, D; Price, RI; Prince, RL; St John, A, 1995) |
| "In conclusion, the further increase in bone resorption by thyroid hormone is predisposed by menopausal changes in bone turnover." | 1.28 | Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. ( Límanová, Z; Stĕpán, JJ, 1992) |
| "To determine whether the osteopenia of rheumatoid arthritis (RA) is due to reduction of trabecular bone mass (TBV) and/or cortical width (CW), we evaluated these parameters by bone histomorphometry; we also measured the calciotropic hormones parathormone(PTH) and calcitonin (CT), vitamin D [25(OH)D] and the biological markers of bone remodeling in a group of patients with RA." | 1.28 | Osteopenia in rheumatoid arthritis: a biochemical, hormonal and histomorphometric study. ( Cabranes, JA; Gomez-Castresana, F; Hernandez, ER; Rico, H; Valor, R; Yague, M, 1990) |
| " The most sensitive marker was vaginal cytology, with the E2 dosage reverting the maturation index to premenopausal values." | 1.27 | Estrogen replacement therapy by transdermal estradiol administration. ( DeFazio, JL; Eggena, P; Hershman, JM; Judd, HL; Laufer, LR; Lu, JK; Meldrum, DR; Sambhi, MP, 1983) |
| "Ours results indicate an increase of bone resorption as a cause of postmenopausal osteoporosis." | 1.27 | Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause. ( Bordiu, E; Charro, A; Depablos, I; Espinos, D; Hernandez, ER; Rico, H, 1984) |
| "We conducted a dose-response study in 23 postmenopausal women to compare the physiologic effects of transdermal estradiol and oral conjugated equine estrogens." | 1.27 | Biologic effects of transdermal estradiol. ( Alkjaersig, NK; Chetkowski, RJ; Eggena, P; Fletcher, AP; Hershman, JM; Judd, HL; Lu, JK; Meldrum, DR; Randle, D; Steingold, KA, 1986) |
| "Osteoporosis is a common complication of corticosteroid therapy and it is associated with both decreased bone formation and increased bone resorption." | 1.27 | Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal women. ( Hartley, TF; Need, AG; Nordin, BE; Philcox, JC, 1986) |
| "Treatment with ethinyl estradiol or norethindrone reduces the bone-turnover rate and plasma calcium levels in normal postmenopausal women, without affecting the secretion of calcium-regulating hormones." | 1.27 | Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. ( Peacock, M; Selby, PL, 1986) |
| "2." | 1.26 | The relation between bone loss and calcium balance in women. ( Crilly, RG; Horsman, A; Marshall, DH; Nordin, BE; Simpson, M, 1980) |
| "Rapid bone loss, high bone resorption and low calcium absorption are shown to be associated with poor oestrogen status, with crush fracture cases presenting an exaggerated view of the normal post-menopausal situation." | 1.26 | The relationship between oestrogen status and bone loss in post-menopausal women. ( Brook, R; Horsman, A; Nordin, BE; Williams, DA, 1976) |
| "Before treatment, bone resorption was greater than normal in all but one patient and bone formation was normal." | 1.25 | Effect of sex hormones on bone in primary osteoporosis. ( Jones, JD; Jowsey, J; Kelly, PJ; Maher, FT; Riggs, BL, 1969) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 85 (72.03) | 18.7374 |
| 1990's | 27 (22.88) | 18.2507 |
| 2000's | 5 (4.24) | 29.6817 |
| 2010's | 1 (0.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Recker, RR | 1 |
| Lappe, JM | 1 |
| Davies, M | 1 |
| Kimmel, D | 1 |
| Parker, CR | 1 |
| Blackwell, PJ | 1 |
| Freemont, AJ | 1 |
| Hosking, DJ | 1 |
| JASANI, C | 2 |
| NORDIN, BE | 27 |
| SMITH, DA | 2 |
| SWANSON, I | 1 |
| Löfman, O | 1 |
| Magnusson, P | 1 |
| Toss, G | 1 |
| Larsson, L | 1 |
| Lee, YH | 1 |
| Hyun, SH | 1 |
| Choung, SY | 1 |
| Brown, JP | 1 |
| Delmas, PD | 2 |
| Malaval, L | 1 |
| Edouard, C | 1 |
| Chapuy, MC | 1 |
| Meunier, PJ | 1 |
| Gallagher, JC | 8 |
| Riggs, BL | 5 |
| DeLuca, HF | 1 |
| Lobo, RA | 1 |
| McCormick, W | 1 |
| Singer, F | 1 |
| Roy, S | 1 |
| Marcus, R | 3 |
| Madvig, P | 1 |
| Crim, M | 1 |
| Pont, A | 1 |
| Kosek, J | 1 |
| Christiansen, C | 6 |
| Rødbro, P | 3 |
| Tjellesen, L | 2 |
| Laufer, LR | 1 |
| DeFazio, JL | 1 |
| Lu, JK | 2 |
| Meldrum, DR | 3 |
| Eggena, P | 2 |
| Sambhi, MP | 1 |
| Hershman, JM | 2 |
| Judd, HL | 3 |
| Aloia, JF | 1 |
| Vaswani, AN | 1 |
| Yeh, JK | 1 |
| Ellis, K | 1 |
| Cohn, SH | 1 |
| Rico, H | 2 |
| Charro, A | 1 |
| Depablos, I | 1 |
| Bordiu, E | 1 |
| Hernandez, ER | 2 |
| Espinos, D | 1 |
| Corghi, E | 1 |
| Ortolani, S | 1 |
| Bianchi, ML | 1 |
| Favini, P | 1 |
| Vigo, P | 1 |
| Polli, EE | 1 |
| Ouyang, PC | 2 |
| Huang, SC | 2 |
| Hsieh, CY | 2 |
| Chen, RJ | 1 |
| Chow, SN | 2 |
| Broulik, PD | 1 |
| Stĕpán, J | 1 |
| Pacovský, V | 2 |
| Marshall, RW | 1 |
| Selby, PL | 2 |
| Chilvers, DC | 1 |
| Hodgkinson, A | 2 |
| Horowitz, M | 9 |
| Need, AG | 11 |
| Philcox, JC | 3 |
| Statland, BE | 1 |
| Winkel, P | 1 |
| Goulding, A | 2 |
| Heyburn, PJ | 1 |
| Peacock, M | 2 |
| Horsman, A | 8 |
| Aaron, J | 3 |
| Marshall, D | 1 |
| Crilly, RG | 5 |
| Gasser, AB | 1 |
| Depierre, D | 1 |
| Mermillod, B | 1 |
| Courvoisier, B | 1 |
| Rico Lenza, H | 1 |
| Thompson, T | 1 |
| Christensen, MS | 1 |
| Larsen, NE | 2 |
| Transbøl, IB | 1 |
| Mandel, FP | 1 |
| Davidson, BJ | 1 |
| Erlik, Y | 1 |
| Burnell, JM | 1 |
| Baylink, DJ | 1 |
| Chestnut, CH | 1 |
| Mathews, MW | 1 |
| Teubner, EJ | 1 |
| Cohen, L | 1 |
| Kitzes, R | 1 |
| Schubert, L | 1 |
| Livello, ML | 1 |
| Belloni, M | 1 |
| Polvani, F | 1 |
| Jones, MM | 1 |
| Marshall, DH | 8 |
| Simpson, M | 1 |
| Prince, RL | 2 |
| Dick, I | 2 |
| Devine, A | 1 |
| Price, RI | 1 |
| Gutteridge, DH | 1 |
| Kerr, D | 1 |
| Criddle, A | 1 |
| Garcia-Webb, P | 2 |
| St John, A | 1 |
| Elders, PJ | 1 |
| Lips, P | 1 |
| Netelenbos, JC | 1 |
| van Ginkel, FC | 1 |
| Khoe, E | 1 |
| van der Vijgh, WJ | 1 |
| van der Stelt, PF | 1 |
| Guañabens, N | 1 |
| Parés, A | 1 |
| Navasa, M | 1 |
| Martínez de Osaba, MJ | 1 |
| Hernández, ME | 1 |
| Muñoz, J | 1 |
| Rodés, J | 1 |
| Gallacher, SJ | 1 |
| Fenner, JA | 1 |
| Fisher, BM | 1 |
| Quin, JD | 1 |
| Fraser, WD | 1 |
| Logue, FC | 1 |
| Cowan, RA | 1 |
| Boyle, IT | 1 |
| MacCuish, AC | 1 |
| Seibel, MJ | 1 |
| Cosman, F | 1 |
| Shen, V | 1 |
| Gordon, S | 1 |
| Dempster, DW | 1 |
| Ratcliffe, A | 1 |
| Lindsay, R | 5 |
| Morris, HA | 7 |
| Barger-Lux, MJ | 1 |
| Heaney, RP | 1 |
| Peh, CA | 1 |
| Wishart, JM | 2 |
| Eggelmeijer, F | 1 |
| Papapoulos, SE | 1 |
| Westedt, ML | 1 |
| Van Paassen, HC | 2 |
| Dijkmans, BA | 1 |
| Breedveld, FC | 1 |
| Melis, GB | 1 |
| Cagnacci, A | 2 |
| Bruni, V | 1 |
| Falsetti, L | 1 |
| Jasonni, VM | 1 |
| Nappi, C | 1 |
| Polatti, F | 1 |
| Volpe, A | 2 |
| Langdahl, BL | 2 |
| Loft, AG | 1 |
| Møller, N | 1 |
| Weeke, J | 1 |
| Eriksen, EF | 2 |
| Mosekilde, L | 1 |
| Charles, P | 1 |
| Leino, A | 1 |
| Impivaara, O | 1 |
| Kaitsaari, M | 1 |
| Itoi, H | 1 |
| Minakami, H | 1 |
| Sato, I | 1 |
| Amram, A | 1 |
| Battaglia, C | 1 |
| Knapen, MH | 2 |
| Nieuwenhuijzen Kruseman, AC | 1 |
| Wouters, RS | 1 |
| Vermeer, C | 2 |
| Løkke, E | 1 |
| Carstens, M | 1 |
| Stenkjaer, LL | 1 |
| Scopacasa, F | 1 |
| Hart, DM | 7 |
| Aitken, JM | 1 |
| MacDonald, EB | 1 |
| Anderson, JB | 1 |
| Clarke, AC | 1 |
| Guha, P | 1 |
| Hanes, F | 1 |
| Oldfield, W | 1 |
| Purdie, D | 1 |
| Ferguson, MM | 1 |
| Clark, AS | 1 |
| Kraszewski, A | 2 |
| Maclean, A | 1 |
| Garwood, J | 1 |
| Clark, AC | 1 |
| Crilly, R | 1 |
| Cawood, M | 1 |
| Dequeker, J | 2 |
| Burssens, A | 1 |
| Creytens, G | 1 |
| Bouillon, R | 1 |
| Goldsmith, RS | 1 |
| Jowsey, J | 2 |
| Dubé, WJ | 1 |
| Arnaud, CD | 1 |
| Kelly, PJ | 3 |
| Brook, R | 1 |
| Williams, DA | 1 |
| Aaron, JE | 1 |
| Nordin, EC | 1 |
| Meier, DE | 1 |
| Luckey, MM | 1 |
| Wallenstein, S | 1 |
| Lapinski, RH | 1 |
| Catherwood, B | 1 |
| Purdie, DW | 1 |
| Hay, AW | 1 |
| Everett, M | 1 |
| Stĕpán, JJ | 2 |
| Límanová, Z | 1 |
| Schoutens, A | 1 |
| Laurent, E | 1 |
| Markowicz, E | 1 |
| Lisart, J | 1 |
| De Maertelaer, V | 1 |
| Mazess, RB | 1 |
| Barden, HS | 1 |
| Cleghorn, DB | 1 |
| De Nichilo, D | 1 |
| Fletcher, CD | 1 |
| Farish, E | 1 |
| Leggate, J | 1 |
| Joborn, C | 1 |
| Ljunghall, S | 1 |
| Larsson, K | 1 |
| Lindh, E | 1 |
| Naessén, T | 1 |
| Wide, L | 1 |
| Akerström, G | 1 |
| Rastad, J | 1 |
| Packer, E | 1 |
| Holloway, L | 1 |
| Newhall, K | 1 |
| Kanwar, G | 1 |
| Butterfield, G | 1 |
| Retallack, RW | 1 |
| Gomez-Castresana, F | 1 |
| Yague, M | 1 |
| Cabranes, JA | 1 |
| Valor, R | 1 |
| Smith, ML | 1 |
| Fogelman, I | 1 |
| Scott, E | 1 |
| Bevan, J | 1 |
| Leggate, I | 3 |
| Pocock, NA | 1 |
| Sambrook, PN | 1 |
| Eisman, JA | 1 |
| Hamulyák, K | 1 |
| Adami, S | 1 |
| Suppi, R | 1 |
| Bertoldo, F | 1 |
| Rossini, M | 1 |
| Residori, M | 1 |
| Maresca, V | 1 |
| Lo Cascio, V | 1 |
| Pospíchal, J | 1 |
| Presl, J | 1 |
| Tsai, KS | 1 |
| Ebeling, PR | 1 |
| Minkoff, JR | 1 |
| Young, G | 1 |
| Grant, B | 1 |
| Thomsen, K | 1 |
| Riis, BJ | 3 |
| Johansen, JS | 1 |
| Stock, JL | 1 |
| Coderre, JA | 1 |
| Mallette, LE | 1 |
| Chetkowski, RJ | 1 |
| Steingold, KA | 1 |
| Randle, D | 1 |
| Alkjaersig, NK | 1 |
| Fletcher, AP | 1 |
| Johansen, J | 1 |
| Polley, KJ | 1 |
| Horowitz, H | 1 |
| Mazzuoli, GF | 1 |
| Passeri, M | 1 |
| Gennari, C | 3 |
| Minisola, S | 2 |
| Antonelli, R | 2 |
| Valtorta, C | 2 |
| Palummeri, E | 1 |
| Cervellin, GF | 1 |
| Gonnelli, S | 2 |
| Francini, G | 1 |
| Hartley, TF | 2 |
| Brincat, M | 1 |
| Kabalan, S | 1 |
| Studd, JW | 1 |
| Moniz, CF | 1 |
| de Trafford, J | 1 |
| Montgomery, J | 1 |
| Wishart, J | 2 |
| Roberts, AD | 1 |
| Cordiner, JW | 1 |
| Barlow, DH | 1 |
| MacRae, D | 1 |
| Civitelli, R | 1 |
| Zacchei, F | 1 |
| Bigazzi, S | 1 |
| Vattimo, A | 1 |
| Avioli, LV | 1 |
| Duda, RJ | 1 |
| Kumar, R | 1 |
| Nelson, KI | 1 |
| Zinsmeister, AR | 1 |
| Mann, KG | 1 |
| Kuntz, D | 1 |
| Marie, P | 1 |
| Berhel, M | 1 |
| Caulin, F | 1 |
| Pødenphant, J | 1 |
| Larking, PW | 1 |
| McDonald, BW | 1 |
| Taylor, ML | 1 |
| Kirkland, AD | 1 |
| Verstraeten, A | 1 |
| Duursma, SA | 1 |
| Bijlsma, JW | 1 |
| Slootweg, MC | 1 |
| Morris, H | 1 |
| Philcox, J | 1 |
| Abdalla, HI | 1 |
| Hooke, A | 1 |
| Mazzuoli, G | 1 |
| Tabolli, S | 1 |
| Bigi, F | 1 |
| Stuchlĩkovã, E | 1 |
| Jelĩnkovã, M | 1 |
| Smrz, M | 1 |
| Wilkinson, R | 3 |
| Caniggia, A | 2 |
| Strauss, G | 1 |
| Harding, JJ | 1 |
| Wesley, JM | 1 |
| Young, MM | 1 |
| Jones, JD | 1 |
| Maher, FT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass[NCT01928082] | Phase 2 | 1 participants (Actual) | Interventional | 2013-08-01 | Terminated (stopped due to The fellow conducting the recruitment and screening left the institution) | ||
| Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model[NCT04051320] | Phase 2 | 23 participants (Actual) | Interventional | 2020-01-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"This outcome measure determines the degree of irritability and reactive aggression in HS+ during hormone addback and its relationship to the target population. Irritability will be defined as score on the IDAS Ill Temper Scale. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~The Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to ac" (NCT04051320)
Timeframe: Endpoint (week 6)
| Intervention | correlation coefficient (Number) |
|---|---|
| Hormone Sensitive Women (HS+) | 0.18 |
| Hormone Insensitive Women (HS-) | 0.03 |
"This outcome measure determines the degree of subcortical (amygdala, caudate, putamen, and nucleus accumbens) activation in HS+ during hormone addback and it's relationship to the target population. The activation in amygdala and ventral striatum (caudate, putamen, nucleus accumbens) regions of interest (ROIs) will be assessed during the Affective Posner Task.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: Endpoint (week 6)
| Intervention | correlation coefficient (Number) |
|---|---|
| Hormone Sensitive Women (HS+) | 0.47 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper (i.e., irritability) Scale and threat attention bias. (NCT04051320)
Timeframe: Endpoint (week 6)
| Intervention | correlation coefficient (Number) |
|---|---|
| Hormone Sensitive Women (HS+) | -0.35 |
| Hormone Insensitive Women (HS-) | 0.11 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)
| Intervention | correlation coefficient (Mean) |
|---|---|
| Hormone Sensitive Women (HS+) | -0.13 |
| Hormone Insensitive Women (HS-) | 0.49 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)
| Intervention | correlation coefficient (Number) |
|---|---|
| Hormone Sensitive Women (HS+) | -0.57 |
| Hormone Insensitive Women (HS-) | -0.08 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Arbitrary Units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | -0.009866667 | -0.086876444 |
| Hormone Sensitive Women (HS+) | 0.005316917 | -0.047401917 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Arbitrary Units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.0077258 | -0.049988 |
| Hormone Sensitive Women (HS+) | -0.043943333 | 0.059099917 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Arbitrary Units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.0691907 | -0.072512 |
| Hormone Sensitive Women (HS+) | -0.028451818 | 0.031632727 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Arbitrary Units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.0383029 | -0.021029 |
| Hormone Sensitive Women (HS+) | -0.001223462 | 0.048155385 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Arbitrary Units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.037334 | -0.15643 |
| Hormone Sensitive Women (HS+) | -0.04544 | 0.022654 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Arbitrary Units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.061407 | 0.0058011 |
| Hormone Sensitive Women (HS+) | -0.069919077 | 0.045146154 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Arbitrary Units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.052685333 | -0.006394444 |
| Hormone Sensitive Women (HS+) | 0.044384167 | -0.005181667 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Arbitrary Units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.002542222 | -0.080736333 |
| Hormone Sensitive Women (HS+) | -0.007560692 | 0.036225385 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | arbitrary units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.0213 | 0.00111 |
| Hormone Sensitive Women (HS+) | 0.0247 | -0.0192 |
"This outcome measure determines the extent to which HS+ is characterized by reactive aggression during hormone addback relative to baseline in the target population. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to accrue money or press another button to subtract money from a (fictional) partner at no direct gain to themselves. Frustration is induced by periodic subtractions of their own money, which is attributed to the partner." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | Number of subtraction responses (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 129.20 | 54.90 |
| Hormone Sensitive Women (HS+) | 103.08 | 34.62 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) Blood-oxygen-level-dependent (BOLD) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | arbitrary units (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 0.0533 | 0.00804 |
| Hormone Sensitive Women (HS+) | 0.0174 | -0.0114 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS- by examining threat attention bias assessed during the visual dot-probe paradigm.~The Visual Dot-Probe Paradigm asks participants to detect a target stimulus that is embedded in a matrix of distracting stimuli (e.g., a target stimulus, an angry face, might be embedded in a matrix of neutral distractor faces). Attention biases are inferred from faster response times to detect a threatening stimulus in a matrix of neutral stimuli relative to response time to detect neutral stimuli in neutral matrices. Thus, positive times reflect attention bias toward threat, whereas negative times reflect attention bias away from threat." (NCT04051320)
Timeframe: up to 6 weeks
| Intervention | attention bias in milliseconds (Mean) | |
|---|---|---|
| Baseline (Visit 3) | Hormone Addback (Visit 6) | |
| Hormone Insensitive Women (HS-) | 36.92 | -42.35 |
| Hormone Sensitive Women (HS+) | -0.57 | -9.04 |
5 reviews available for hydroxyproline and Menopause
| Article | Year |
|---|---|
Usefulness of clinical chemistry measurements in classifying patients with breast cancer.
Topics: Alkaline Phosphatase; Apolipoproteins; Apolipoproteins D; beta 2-Microglobulin; Breast Neoplasms; Ca | 1982 |
Osteoporosis and osteomalacia.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Calcium; Estrogens; Female; Fractures, Bone; Huma | 1980 |
Ageing of bone: its relation to osteoporosis and osteoarthrosis in post-menopausal women.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Bone and Bones; Bone Development; Bone Diseases; Cal | 1975 |
What do we know about biochemical bone markers?
Topics: Adult; Aged; Alkaline Phosphatase; Biomarkers; Bone Matrix; Bone Remodeling; Bone Resorption; Female | 1991 |
Calcium and osteoporosis.
Topics: Bone Resorption; Calcium; Calcium, Dietary; Female; Humans; Hydroxyproline; Menopause; Nutritional R | 1988 |
26 trials available for hydroxyproline and Menopause
| Article | Year |
|---|---|
Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis.
Topics: Aged; Calcitriol; Calcium; Clinical Trials as Topic; Dihydroxycholecalciferols; Estrogens, Conjugate | 1980 |
Serum alkaline phosphatase during hormone treatment in early postmenopausal women. A model for establishing optimal prophylaxis and treatment in postmenopausal osteoporosis.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Clinical Trials as Topic; Estradiol; Estriol; Est | 1984 |
Effect of 1,25-dihydroxyvitamin D3 on biochemical indices of bone turnover in postmenopausal women.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcitriol; Calcium; Female; Humans; Hy | 1984 |
Effect of calcium supplementation on urinary hydroxyproline in osteoporotic postmenopausal women.
Topics: Aged; Bone and Bones; Calcium, Dietary; Creatinine; Female; Humans; Hydroxyproline; Menopause; Middl | 1984 |
Free serum hydroxyproline and total urinary hydroxyproline for the detection of skeletal metastasis.
Topics: Adult; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trial | 1982 |
Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Calcium; Dose-Response Relationship, Drug; Estrogens; F | 1982 |
Long-term effect of calcium supplementation on bone loss in perimenopausal women.
Topics: Alkaline Phosphatase; Body Mass Index; Body Weight; Bone Density; Calcium; Female; Humans; Hydroxypr | 1994 |
Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis.
Topics: Adult; Aged; Alkaline Phosphatase; Bilirubin; Biomarkers; Bone Density; Calcifediol; Calcitriol; Cal | 1994 |
The effect of chlorothiazide on bone-related biochemical variables in normal post-menopausal women.
Topics: Acid-Base Equilibrium; Aged; Biomarkers; Body Weight; Bone Resorption; Calcium; Chlorothiazide; Crea | 1993 |
Skeletal responsiveness to thyroid hormone is not altered at menopause.
Topics: Alkaline Phosphatase; Amino Acids; Blood Chemical Analysis; Blood Gas Analysis; Bone Density; Bone R | 1996 |
Biochemical aspects of hormonal contraception: effects on bone metabolism.
Topics: Alkaline Phosphatase; Bone Density; Bone Remodeling; Contraceptives, Oral, Combined; Contraceptives, | 1997 |
Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Brain Injuries; Calcium; Castration; C | 1976 |
The effect of 1alpha-hydroxycholecalciferol and hormone therapy on the calcium balance of post-menopausal osteoporosis.
Topics: Bone and Bones; Bone Regeneration; Bone Resorption; Calcium; Clinical Trials as Topic; Ethinyl Estra | 1977 |
Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women.
Topics: Adult; Bone and Bones; Bone Regeneration; Bone Resorption; Clinical Trials as Topic; Creatinine; Dou | 1978 |
Bone loss during oestriol therapy in postmenopausal women.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Calcium; Clinical Trials as Topic; Creatine; Double-Bli | 1979 |
Short term effects of SHD 386L and levonorgestrel on bone and mineral metabolism in the postmenopause: a double-blind randomised placebo-controlled trial.
Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Creatinine; Double-Blind Method; Estradiol; Female; F | 1992 |
Effect of etidronate disodium on bone turnover following surgical menopause.
Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Calcium-Binding Proteins; Etidronic Acid; Female; Hum | 1989 |
Transdermal estradiol in the treatment of postmenopausal bone loss.
Topics: Administration, Cutaneous; Alkaline Phosphatase; Bone and Bones; Calcium; Clinical Trials as Topic; | 1989 |
Prospective trial of ossein-hydroxyapatite compound in surgically induced postmenopausal women.
Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Collagen; Creatinine; Female; Human | 1989 |
Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium-Binding Proteins; Clinical Trials as | 1987 |
Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women.
Topics: Alkaline Phosphatase; Biochemical Phenomena; Biochemistry; Bone and Bones; Calcium; Calcium-Binding | 1988 |
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.
Topics: Aged; Bone and Bones; Calcitonin; Calcium; Clinical Trials as Topic; Creatinine; Double-Blind Method | 1986 |
Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
Topics: Administration, Oral; Alkaline Phosphatase; Biopsy; Bone and Bones; Calcitonin; Calcium; Clinical Tr | 1986 |
Hydroxyproline/creatinine ratios as estimates of bone resorption in early postmenopausal women. Fasting and 24-h urine samples compared.
Topics: Bone Resorption; Clinical Trials as Topic; Creatinine; Double-Blind Method; Drug Combinations; Estra | 1986 |
Prevention of bone mineral loss in postmenopausal women by norethisterone.
Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Creatinine; Drug Evaluation; Female; Humans; Hydroxyp | 1985 |
Sites and modes of action of an estrogen-gestagen combination on calcium and phosphate metabolism in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Analysis of Variance; Calcium; Calcium Isotopes; C | 1972 |
87 other studies available for hydroxyproline and Menopause
| Article | Year |
|---|---|
Perimenopausal bone histomorphometry before and after menopause.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Female; Human | 2018 |
Biochemical measurements in the prediction of histologic subtype of renal transplant bone disease in women.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Chronic K | 2002 |
SPINAL OSTEOPOROSIS AND THE MENOPAUSE.
Topics: Blood; Bone Resorption; Calcium; Ethinyl Estradiol; Female; Fluids and Secretions; Glycerophosphates | 1965 |
Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study.
Topics: Adult; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Remodeling; Calcium; Cross-Section | 2005 |
Effect of herbal extract mixture on menopausal urinary incontinence in ovariectomized rats.
Topics: Acetylcholine; Analysis of Variance; Animals; Body Weight; Collagen; Cucurbita; Dose-Response Relati | 2006 |
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Resorption; Calcium-Binding Proteins; Femal | 1984 |
Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women.
Topics: Adult; Calcium; Creatinine; Delayed-Action Preparations; Estradiol; Estrogens, Conjugated (USP); Est | 1984 |
Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism.
Topics: Adult; Aged; Alkaline Phosphatase; Biopsy; Calcitriol; Calcium; Cyclic AMP; Drug Evaluation; Estroge | 1984 |
Estrogen replacement therapy by transdermal estradiol administration.
Topics: Calcium; Climacteric; Creatinine; Double-Blind Method; Estradiol; Estrone; Female; Follicle Stimulat | 1983 |
Sodium excess in postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Calcium; Female; Humans; Hydroxyproline; Menopause; Middle Aged; Neutron | 1983 |
Lack of hormonal changes in postmenopausal women of equal weight with and without osteoporosis, including relation to time of menopause.
Topics: Age Factors; Aged; Body Weight; Bone Resorption; Creatinine; Estrogens; Female; Hormones; Humans; Hy | 1984 |
Basal plasma levels of calcitonin and bone mineral mass in normal and uremic women. Effect of menopause.
Topics: Adult; Aged; Bone and Bones; Calcitonin; Female; Humans; Hydroxyproline; Menopause; Middle Aged; Min | 1984 |
Serum total estrogen levels and urinary excretion of calcium and hydroxyproline in premenopausal and postmenopausal Chinese women.
Topics: Adult; Aged; Calcium; Estrogens; Female; Humans; Hydroxyproline; Menopause; Middle Aged; Taiwan | 1984 |
The activity of the bone isoenzyme of serum alkaline phosphatase and urinary hydroxyproline excretion in premenopausal and postmenopausal women with primary hyperparathyroidism.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bone and Bones; Calcium; Estrogens; Female; Humans; Hydroxy | 1984 |
The effect of ethinyl oestradiol on calcium and bone metabolism in peri- and postmenopausal women.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Calcium; Creatinine; Ethinyl Estradiol; Female; Humans; | 1984 |
Fasting urinary sodium/creatinine in relation to calcium/creatinine and hydroxyproline/creatinine in a general population of women.
Topics: Adolescent; Adult; Aged; Bone Resorption; Calcium; Creatinine; Diet; Fasting; Female; Humans; Hydrox | 1981 |
Smoking, the menopause and biochemical parameters of bone loss and bone turnover.
Topics: Age Factors; Bone and Bones; Bone Resorption; Calcium; Creatinine; Female; Humans; Hydroxyproline; M | 1982 |
[Prolactin and estrogens in osteoporosis in post-menopausal women (author's transl)].
Topics: Aged; Alkaline Phosphatase; Estrogens; Female; Humans; Hydroxyproline; Menopause; Middle Aged; Osteo | 1982 |
Measurement of the fasting urinary hydroxyproline: creatinine ratio in normal adults and its variation with age and sex.
Topics: Adolescent; Adult; Age Factors; Aged; Creatinine; Fasting; Female; Humans; Hydroxyproline; Male; Men | 1982 |
Effects of progestins on bone metabolism in postmenopausal women.
Topics: Administration, Oral; Bone and Bones; Calcium; Creatinine; Dose-Response Relationship, Drug; Double- | 1982 |
Bone matrix and mineral abnormalities in postmenopausal osteoporosis.
Topics: Adult; Age Factors; Aged; Bone and Bones; Calcium; Carbonates; Female; Humans; Hydroxyproline; Magne | 1982 |
Infrared spectroscopy and magnesium content of bone mineral in osteoporotic women.
Topics: Aged; Bone and Bones; Creatinine; Female; Humans; Hydroxyproline; Magnesium; Menopause; Middle Aged; | 1981 |
Changes in calcium absorption during hormonal replacement therapy in postmenopausal osteoporosis.
Topics: Calcium; Cyclofenil; Estradiol; Female; Humans; Hydroxyproline; Intestinal Absorption; Menopause; Mi | 1981 |
Rise in plasma alkaline phosphatase at the menopause.
Topics: Alkaline Phosphatase; Female; Humans; Hydroxyproline; Menopause; Osteoporosis | 1980 |
The relation between bone loss and calcium balance in women.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Regeneration; Bone Resorption; Calcium; Female; Fem | 1980 |
The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90.
Topics: Adult; Aged; Aged, 80 and over; Aging; Alkaline Phosphatase; Bone Development; Bone Resorption; Calc | 1995 |
An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus.
Topics: Absorptiometry, Photon; Adult; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Calci | 1993 |
Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
Topics: Acid Phosphatase; Adult; Aged; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Collagen; Cro | 1993 |
The nature and significance of the relationship between urinary sodium and urinary calcium in women.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Bone Resorption; Calcium; Calcium, Dietary; Creatini | 1993 |
Effects of calcium restriction on metabolic characteristics of premenopausal women.
Topics: Adult; Calcium; Calcium, Dietary; Fasting; Female; Humans; Hydroxyproline; Menopause; Parathyroid Ho | 1993 |
Bone metabolism in rheumatoid arthritis; relation to disease activity.
Topics: Adult; Aged; Alkaline Phosphatase; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; B | 1993 |
Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.
Topics: Absorptiometry, Photon; Administration, Intranasal; Administration, Intravaginal; Alkaline Phosphata | 1996 |
Measurements of deoxypyridinoline and hydroxyproline in 24-h, first morning, and second morning urine samples.
Topics: Amino Acids; Bone Resorption; Chromatography, High Pressure Liquid; Collagen; Female; Humans; Hydrox | 1996 |
Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1-alpha-hydroxyvitamin D3 and calcium lactate on vertebral bone loss in early menopausal women.
Topics: Administration, Oral; Adult; Alkaline Phosphatase; Bone Density; Calcium; Estriol; Estrogen Replacem | 1997 |
Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10 years after menopause.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Body Heigh | 1998 |
Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene.
Topics: Adult; Aged; Animals; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Case-Control Studi | 2000 |
Effects of dose and timing of calcium supplementation on bone resorption in early menopausal women.
Topics: Amino Acids; Bone Resorption; Calcium; Creatinine; Dietary Supplements; Drug Administration Schedule | 2002 |
Metabolic effects of corticosteroid therapy in post-menopausal women.
Topics: Androstenedione; Bone and Bones; Calcium; Creatinine; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1979 |
The prevention and management of post-menopausal osteoporosis.
Topics: Aged; Bone and Bones; Calcium; Creatinine; Estradiol; Ethinyl Estradiol; Female; Humans; Hydroxyprol | 1977 |
The effect of 1alpha-hydroxyvitamin D3 with and without oestrogens on calcium balance in post-menopausal women.
Topics: Calcium; Drug Therapy, Combination; Estrogens; Female; Femoral Neck Fractures; Humans; Hydroxycholec | 1977 |
Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women.
Topics: Adrenal Cortex Hormones; Androstenedione; Creatinine; Estrone; Female; Humans; Hydroxyproline; Menop | 1978 |
The effect of oestradiol valerate and cyclic oestradiol valerate/DL-norgestrel on calcium metabolism.
Topics: Calcium; Estradiol; Female; Humans; Hydroxyproline; Menopause; Norgestrel | 1978 |
Effects of phosphorus supplementation on serum parathyroid hormone and bone morphology in osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Calcium, Dietary; Female; Huma | 1976 |
The relationship between oestrogen status and bone loss in post-menopausal women.
Topics: Aging; Bone Resorption; Calcium; Creatinine; Estrogens; Female; Fractures, Bone; Humans; Hydroxyprol | 1976 |
Post-menopausal osteopenia and osteoporosis.
Topics: Adult; Bone and Bones; Bone Resorption; Calcium; Creatinine; Female; Humans; Hydroxyproline; Male; M | 1975 |
Effects of oestrogen and progestogen therapy on calcium metabolism in post-menopausal women.
Topics: Calcium; Creatinine; Estriol; Ethinyl Estradiol; Female; Humans; Hydroxyproline; Kidney Tubules; Men | 1975 |
Racial differences in pre- and postmenopausal bone homeostasis: association with bone density.
Topics: Adult; Aged; Alkaline Phosphatase; Black People; Bone and Bones; Bone Density; Calcium; Female; Home | 1992 |
Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Bone D | 1992 |
Serum triiodothyronine, bone turnover, and bone mass changes in euthyroid pre- and postmenopausal women.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Density; Estradiol; Estrogens; Female; Humans; Hyd | 1991 |
Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking, and birth-control pills.
Topics: Adult; Age Factors; Analysis of Variance; Bone Density; Calcium; Calcium, Dietary; Contraceptives, O | 1991 |
Effect of salt restriction on urine hydroxyproline excretion in postmenopausal women.
Topics: Aged; Bone Resorption; Calcium; Diet, Sodium-Restricted; Female; Humans; Hydroxyproline; Menopause; | 1991 |
Prevention of bone loss by hormone replacement therapy is probably not due to stimulation of calcitonin secretion.
Topics: Alkaline Phosphatase; Bone and Bones; Calcitonin; Calcium; Creatinine; Estrogen Replacement Therapy; | 1991 |
Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement.
Topics: Adult; Bone and Bones; Calcium; Electrolytes; Estrogen Replacement Therapy; Ethinyl Estradiol; Femal | 1991 |
Effects of estrogen on daylong circulating calcium, phosphorus, 1,25-dihydroxyvitamin D, and parathyroid hormone in postmenopausal women.
Topics: Aged; Calcitriol; Calcium; Circadian Rhythm; Creatine; Cyclic AMP; Estrogens; Female; Humans; Hydrox | 1990 |
The effects of the menopause on calcitriol and parathyroid hormone: responses to a low dietary calcium stress test.
Topics: Adult; Calcitriol; Calcium; Calcium, Dietary; Estrogens; Female; Humans; Hydroxyproline; Menopause; | 1990 |
Osteopenia in rheumatoid arthritis: a biochemical, hormonal and histomorphometric study.
Topics: Adult; Aged; Aging; Arthritis, Rheumatoid; Bone and Bones; Bone Diseases, Metabolic; Calcitonin; Cal | 1990 |
Age and menopause-related changes in indices of bone turnover.
Topics: Adult; Age Factors; Aged; Bone and Bones; Bone Density; Female; Follicle Stimulating Hormone; Humans | 1989 |
The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion.
Topics: Adult; Aged; Calcium; Data Interpretation, Statistical; Durapatite; Female; Humans; Hydroxyapatites; | 1989 |
Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women.
Topics: Age Factors; Aged; Bone and Bones; Bone Density; Calcium; Female; Humans; Hydroxyproline; Infusions, | 1989 |
Interactions of medroxyprogesterone acetate with estrogen on the calcium-parathyroid axis in post-menopausal women.
Topics: Adult; Aged; Calcium; Drug Therapy, Combination; Estrogens; Female; Humans; Hydroxyproline; Medroxyp | 1986 |
Effects of a short course of estrogen on mineral metabolism in postmenopausal women.
Topics: Adult; Calcitriol; Calcium; Calcium-Binding Proteins; Creatinine; Cyclic AMP; Estrogens; Female; Glo | 1985 |
Biologic effects of transdermal estradiol.
Topics: Administration, Oral; Administration, Topical; Blood Coagulation Factors; Calcium; Carrier Proteins; | 1986 |
Effect of estrogen (Premarin) replacement therapy on serum level of total estrogen and urinary excretion of calcium and hydroxyproline in postmenopausal Chinese women.
Topics: Adult; Aged; Bone and Bones; Calcium; Creatinine; Estrogens; Estrogens, Conjugated (USP); Female; Hu | 1986 |
Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
Topics: Absorption; Aged; Bone and Bones; Calcium; Calcium Radioisotopes; Female; Humans; Hydroxyproline; Me | 1987 |
A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman.
Topics: Bone and Bones; Collagen; Female; Follicle Stimulating Hormone; Humans; Hydroxyproline; Menopause; M | 1987 |
Biochemical effects of calcium supplementation in postmenopausal osteoporosis.
Topics: Alkaline Phosphatase; Bone Resorption; Calcium; Creatinine; Female; Humans; Hydroxyproline; Menopaus | 1988 |
The variation in cervical hydroxyproline and cervical water with age.
Topics: Adult; Aged; Aging; Body Water; Cervix Uteri; Collagen; Female; Humans; Hydroxyproline; Menopause; M | 1988 |
Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
Topics: Aging; Biomarkers; Bone Resorption; Calcitonin; Calcium-Binding Proteins; Female; Humans; Hydroxypro | 1988 |
Calcium metabolism and osteoporosis in corticosteroid-treated postmenopausal women.
Topics: Aged; Aged, 80 and over; Calcium; Creatinine; Female; Humans; Hydroxyproline; Menopause; Middle Aged | 1986 |
1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women.
Topics: Alkaline Phosphatase; Calcifediol; Calcitriol; Calcium; Calcium-Binding Proteins; Creatinine; Female | 1987 |
Urine glycosaminoglycans in a reference population: effects of age, body surface area, and postmenopausal status.
Topics: Adult; Aged; Aging; Body Constitution; Circadian Rhythm; Collagen; Female; Glycosaminoglycans; Human | 1987 |
Mineral metabolism in postmenopausal women with active rheumatoid arthritis.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Blood Sedimentation; Calcium; Creatinine; Female; | 1986 |
Oestrogens and bone metabolism: a hypothesis.
Topics: Alkaline Phosphatase; Bone and Bones; Calcium; Ethinyl Estradiol; Female; Growth Hormone; Humans; Hy | 1986 |
Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women.
Topics: Bone Resorption; Calcitriol; Calcium; Ethinyl Estradiol; Female; Humans; Hydroxyproline; Hyperparath | 1986 |
Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density.
Topics: Aged; Bone and Bones; Calcium; Creatinine; Female; Humans; Hydroxyproline; Hyperparathyroidism; Meno | 1987 |
The effect of calcium supplements on plasma alkaline phosphatase and urinary hydroxyproline in postmenopausal women.
Topics: Aged; Alkaline Phosphatase; Bone Resorption; Calcium; Female; Humans; Hydroxyproline; Menopause; Mid | 1985 |
Changes in mineral content and biochemical bone markers at the menopause.
Topics: 1-Carboxyglutamic Acid; Alkaline Phosphatase; Bone and Bones; Creatinine; Female; Humans; Hydroxypro | 1985 |
Treatment with with oestrogens of primary hyperparathyroidism in post-menopausal women.
Topics: Bone Resorption; Calcium; Ethinyl Estradiol; Female; Humans; Hydroxyproline; Hyperparathyroidism; Ki | 1972 |
The digestibility of subcutaneous adipose tissue from women of different ages.
Topics: Adipose Tissue; Adult; Aged; Aging; Body Height; Body Weight; Collagen; Female; Humans; Hydroxyproli | 1971 |
The crush fracture syndrome in postmenopausal women.
Topics: Aged; Aging; Autoanalysis; Biological Transport; Biopsy; Bone and Bones; Calcium Radioisotopes; Calc | 1973 |
Corticosteroid osteoporosis.
Topics: Adult; Aged; Aging; Arthritis, Rheumatoid; Asthma; Autoanalysis; Bone and Bones; Calcium; Calcium Ra | 1973 |
The effect of ethinyloestradiol on calcium and phosphorus metabolism of post-menopausal women with primary hyperparathyroidism.
Topics: Aged; Alkaline Phosphatase; Blood Proteins; Bone Resorption; Calcium; Calcium Radioisotopes; Creatin | 1973 |
[Problems of modern physiopathology of phospho-calcium metabolism].
Topics: Calcium; Calcium Isotopes; Female; Humans; Hydroxyproline; Intestinal Absorption; Intestinal Mucosa; | 1971 |
[Function-dependent differences in the fine structure of the collagen connective tissue in the human uterus].
Topics: Adult; Cervix Uteri; Collagen; Connective Tissue; Connective Tissue Cells; Female; Histocytochemistr | 1969 |
The purification and amino acid composition of human uterus collagens, rheumatoid-arthritis-nodule collagen and ox tendon collagen.
Topics: Adult; Amino Acids; Animals; Autoanalysis; Cattle; Collagen; Elastin; Female; Gelatin; Hexosamines; | 1968 |
Some effects of ethinyl oestradiol on calcium and phosphorus metabolism in osteoporosis.
Topics: Adult; Aged; Bone Resorption; Calcium; Ethinyl Estradiol; Feces; Female; Humans; Hydroxyproline; Men | 1968 |
Effect of sex hormones on bone in primary osteoporosis.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Estrogens; Female; Huma | 1969 |